View Older Stories View More Recent Stories

Nov 11, 2018 08:14AM ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Nov 7, 2018 05:13PM Regeneron (REGN), Sanofi (SNY) announce NEJM published positive detailed results from Praluent cardiovascular outcomes trial
Nov 7, 2018 05:06PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
Nov 7, 2018 05:05PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
Nov 7, 2018 05:01PM New England Journal of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial
Nov 7, 2018 05:00PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
Nov 6, 2018 08:18AM Sanofi (SNY), Regeneron (REGN) Report FDA Priority Review Acceptance of Supplemental Biologics License Application for Dupixent
Nov 6, 2018 08:00AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 6, 2018 06:30AM Regeneron Reports Third Quarter 2018 Financial and Operating Results
Nov 6, 2018 01:01AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 6, 2018 01:00AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 6, 2018 12:59AM FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Oct 26, 2018 07:00AM Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine
Oct 25, 2018 07:29AM Regeneron (REGN) Says EYLEA Injection Improved Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Oct 25, 2018 07:00AM EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Oct 22, 2018 07:03AM Regeneron (REGN) Announces FDA Approves Asthma Indication for Dupixent
Oct 22, 2018 07:00AM FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 22, 2018 06:06AM Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Asthma Indication for Dupixent (dupilumab)
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:58PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 19, 2018 07:00AM Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis
Oct 16, 2018 08:00AM Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 16, 2018 05:45AM Regeneron (REGN) Reports Positive Topline Result in Two Phase 3 Trials Evaluating Dupixent (dupilumab) in Patients with Chronic Rhinosinusitis with Nasal Polyps
Oct 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 16, 2018 01:00AM Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 16, 2018 12:59AM Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps
Oct 8, 2018 06:05PM Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Oct 8, 2018 09:30AM Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018
Sep 28, 2018 04:46PM Regeneron (REGN), Sanofi (SNY) Report Approcal of Libtayo (cemiplimab), the First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:39PM FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 17, 2018 05:49AM Regeneron (REGN), Sanofi (SNY) Highlight Positive Phase 3 Results Presented for Dupixent (dupilumab) at 2018 EADV Congress
Sep 15, 2018 02:04AM Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
Sep 15, 2018 02:03AM Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
Sep 15, 2018 01:59AM Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Sep 13, 2018 07:03AM Regeneron (REGN) Says FDA to Review EYLEA Injection for Treatment of Diabetic Retinopathy
Sep 13, 2018 07:00AM FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Sep 12, 2018 08:00AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018 06:28AM Sanofi (SNY) and Regeneron (REGN) Announce FDA to review sBLA for Praluent Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Sep 12, 2018 01:01AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018 01:00AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018 12:59AM FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Aug 24, 2018 09:30AM Regeneron Announces Upcoming Investor Conference Presentation
Aug 17, 2018 07:01AM Regeneron (REGN) Reports FDA Approval of EYLEA (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Aug 17, 2018 07:00AM FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Aug 16, 2018 07:01AM Regeneron (REGN), Teva (TEVA) Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from OA of Knee or Hip
View More Recent Stories View Older Stories